[{"id":"6e3f6be3-6b8b-473c-9f18-8ce3111ed3d5","acronym":"","url":"https://clinicaltrials.gov/study/NCT05424822","created_at":"2022-06-22T00:55:25.938Z","updated_at":"2024-07-02T16:35:01.349Z","phase":"Phase 1","brief_title":"A Study of JNJ-80948543, a T-cell Redirecting CD79b x CD20 x CD3 Trispecific Antibody, in Participants With Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)","source_id_and_acronym":"NCT05424822","lead_sponsor":"Janssen Research \u0026 Development, LLC","biomarkers":" BCL2","pipe":"","alterations":" ","tags":["BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e JNJ-8543"],"overall_status":"Recruiting","enrollment":" Enrollment 180","initiation":"Initiation: 08/18/2022","start_date":" 08/18/2022","primary_txt":" Primary completion: 07/31/2024","primary_completion_date":" 07/31/2024","study_txt":" Completion: 10/30/2026","study_completion_date":" 10/30/2026","last_update_posted":"2024-05-23"}]